Health ❯ Healthcare ❯ Medical Research

Oncology

Lung Cancer Breast Cancer Prostate Cancer Glioblastoma Acute Myeloid Leukemia Colorectal Cancer Multiple Myeloma Clinical Trials Bladder Cancer Immunotherapy Melanoma Pediatric Oncology Pediatric Cancer Cancer Treatment Head and Neck Cancer Brain Tumors Pancreatic Cancer Ovarian Cancer Hepatocellular Carcinoma Chronic Lymphocytic Leukemia Radiation Therapy Meningiomas Lymphoma Acute Lymphoblastic Leukemia Neuroblastoma Leukemia Gastrointestinal Cancer Brain Cancer Skin Cancer Kidney Cancer Biliary Tract Cancer Cancer Immunotherapy Pathology Small Cell Lung Cancer HPV-positive Oropharyngeal Cancer Large B-Cell Lymphoma Endometrial Cancer Mesothelioma Chemotherapy Cholangiocarcinoma Non-Small Cell Lung Cancer (NSCLC) Nasopharyngeal Carcinoma Hematologic Malignancies Rhabdomyosarcoma Imaging Techniques Diffuse Large B-Cell Lymphoma Follicular Lymphoma Cancer-related Fatigue NUT Carcinoma Acute Myeloid Leukemia (AML) Nuclear Medicine Cancer Diagnosis Chemotherapy Resistance Acute Leukemia Biomarkers Vulvar Cancer Targeted Alpha Therapy Breast Cancer Treatment Cancer Detection Translational Medicine Gastric Cancer Hematologic Cancers Cancer Immunology Melanoma Treatment Cancer Therapies Gene Therapy Childhood Leukemia Gastroesophageal Cancer Cancer Therapeutics Stem Cell Research Radiopharmaceuticals Thyroid Cancer Melanoma Recurrence Precision Oncology Renal Cell Carcinoma Ewing's Sarcoma Oropharyngeal Cancer Lymphomas Tumor Microbiota Radiation Oncology

Abemaciclib Shows Early Benefit Signal in Genetically Selected High-Grade Meningioma Trial

Six-month disease control exceeded historical rates in this nonrandomized phase II study.

Immune Atlas Sharpens Myeloma Risk Prediction as Dual-Target CAR T Counters BCMA Loss

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Study Finds No Added Breast Cancer Risk From Menopausal Hormone Therapy in BRCA Carriers

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Preoperative MRI Fails to Improve Outcomes in Early HR-Negative Breast Cancer

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

GigaTIME AI Converts Routine H&E Slides Into Virtual Spatial Proteomics at Population Scale

AI Multimodal Model Outperforms Oncotype DX for Long-Term Breast Cancer Recurrence Risk

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Swedish Study Ties Lower Ipilimumab Dose to Longer Survival and Less Toxicity in Advanced Melanoma

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

EndRAD Phase 2 Finds Non-TBI Conditioning Matches Outcomes in MRD-Negative Young B-ALL

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer